FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/02/102860 [Registered on: 03/02/2026] Trial Registered Prospectively
Last Modified On: 30/01/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Use Of Kutajadi Tablet Along With Glimepiride Metformin In Diabetes Mellitus II 
Scientific Title of Study   Randomized Controlled Clinical Trial Of Add On Effect Of Kutajadi Tablet Along With Glimepiride-Metformin In Diabetes Mellitus - II 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Nikita Vijay Chavan 
Designation  PG Scholar 
Affiliation  Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate And Research Center Ashta 
Address  Department of Kayachikitsa Dhanvantari Hospital Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Center Ashta Tal Walwa Dist Sangli

Sangli
MAHARASHTRA
416301
India 
Phone  9773644720  
Fax    
Email  nikitachavan880@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Smita Vitthal Lokhande 
Designation  Professor Department of Kayachikitsa 
Affiliation  Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate And Research Center Ashta 
Address  3rd Floor Department of Kayachikitsa Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Center Ashta Tal Walwa Dist Sangli

Sangli
MAHARASHTRA
416301
India 
Phone  8149556591  
Fax    
Email  yoshitpriya@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Smita Vitthal Lokhande 
Designation  Professor Department of Kayachikitsa 
Affiliation  Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate And Research Center Ashta 
Address  3rd Floor Department of Kayachikitsa Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Center Ashta Tal Walwa Dist Sangli

Sangli
MAHARASHTRA
416301
India 
Phone  8149556591  
Fax    
Email  yoshitpriya@gmail.com  
 
Source of Monetary or Material Support  
Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate And Research Center Ashta Tal-Walwa Dist-Sangli Maharastra 416301 India  
 
Primary Sponsor  
Name  Dr Nikita Vijay Chavan 
Address  Department Of Kayachikita Hon Shri Annasaheb Dange Ayurved Medical College and Post Graduate Research Center Ashta Tal-Walwa Dist-Sangli 416301 Maharastra India 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Nikita Vijay Chavan  Hon Shri Annasaheb Dange Ayurved Medical COllege Post Graduate And Research Center Ashta  Department of Kayachikitsa Hon Shri Annasaheb Dange Ayurved Medical College Post Graduate and Research Center Ashta Tal Walwa Dist Sangli 416301 Maharashtra India
Sangli
MAHARASHTRA 
9773644720

nikitachavan880@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical Committee Of Hon Shri Annasaheb Dange Ayurved Medical College And Post Graduate And Research Center Ashta Sangli  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:E119||Type 2 diabetes mellitus without complications. Ayurveda Condition: PRAMEHAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: Kutajadi Tablet, Reference: Sushrut Chikitsa Sthan 11/8, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/ Tablets, Dose: 500(mg), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 90 Days, anupAna/sahapAna: Yes(details: -Koshna jala), Additional Information: -
2Comparator Arm (Non Ayurveda)-(1) Medicine Name: Tablet Glimepiride-Metformin, Reference: NA, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/ Tablets, Dose: (1/500), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 90 Days, anupAna/sahapAna: Yes(details: -Koshna jal)
 
Inclusion Criteria  
Age From  30.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  1.Patients having diagnosis of Diabetes Mellitus II and Age of 30 to 70 years with irrespective of gender, education, religion, socioeconomic status
2.Patients presenting sign and symptoms of Pipasa vridhhi (Polydipsia), Prabhut mutrata (Polyuria), Avila mutrata (Turbidity), Nakta mutrata (Nocturia) etc
3.Urine Sugar will be present
4.Blood sugar levels Fasting 126 to 160 mg per dl
Postprandial sugar 160 to 250 mg per dl
5.HbA1C 6.5 Percent to 8 percent
 
 
ExclusionCriteria 
Details  1. Patients having diagnosis Insulin Dependent Diabetes Mellitus
(DM I)
2. Patients with Diabetes Mellitus II and on Insulin Therapy
3. Patients having disease conditions like Cardio-vascular disease, Macrovascular and Microvascular complications
4. Patients suffering from Hepatic dysfunction, Renal dysfunction or Liver Cirrhosis
5. Pregnant Women and Lactating mother
6. Patient suffering from Diabetes complications 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Alternation 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Kutajadi Tablet is effective along with Glemepiride-Metformin in Diabetes Mellitus II  0 Day,30 Day,60 Day,90 Day 
 
Secondary Outcome  
Outcome  TimePoints 
Decrease HbA1C Level and Symptoms after 90 Days  90 Days 
 
Target Sample Size   Total Sample Size="84"
Sample Size from India="84" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   10/03/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. India ranks second globally, after China, in terms of the number of individuals affected by diabetes mellitus, making it a major public health concern. Type 2 diabetes mellitus (T2DM) has emerged as a significant global health challenge and is expected to remain so due to its chronic nature and potential for serious complications.
According to the National NCD Monitoring Survey (NNMS), the prevalence of diabetes in India was reported to be 9.3% in 2018. Similarly, the International Diabetes Federation (IDF) estimated a prevalence of 9.6% in 2021, with projections indicating a rise to 10.4% by 2030. Along with increasing prevalence, the incidence of diabetes is also steadily rising, placing India among the leading nations affected by this metabolic disorder. The growing burden of diabetes poses significant challenges to healthcare systems and adversely affects the quality of life of individuals. In Ayurveda, Prameha is one of the most elaborately described diseases in classical texts and is considered a major metabolic disorder. It is categorized under Mahagada (a group of grave diseases) due to its chronicity, complexity, complications, and involvement of multiple body systems, particularly the urinary system. The clinical features of Prameha show close resemblance to diabetes mellitus described in modern medicine.
Kutajadi formulation, explained in Chikitsa Sthana of Sushruta Samhita, has been selected for the present study. This classical polyherbal formulation is mentioned to possess Pramehaghna (anti-diabetic) properties in various Ayurvedic texts. Kutajadi Tablet contains herbs predominantly having Tikta and Kashaya Rasa, which play a significant role in correcting Meda Dhatu Dushti and improving metabolic balance. These pharmacodynamic properties suggest its potential in the management of Prameha and related metabolic disorders.Prameha, as described in Ayurveda, can be correlated with diabetes mellitus in contemporary medical science. This metabolic disorder predisposes individuals to chronic microvascular complications such as neuropathy, retinopathy, and nephropathy, as well as macrovascular complications including myocardial infarction and stroke. Classical symptoms of Prameha such as Prabhuta Mutrata, Avila Mutrata, and Pipasa Adhikya closely correlate with polyuria, turbid urine, and polydipsia seen in type 2 diabetes mellitus. In recent times, sedentary lifestyle, lack of physical activity, and improper dietary habits have significantly contributed to the rising prevalence of type 2 diabetes mellitus. Long-term use of synthetic antidiabetic drugs is often associated with adverse effects such as hypoglycemia, weight gain, and gastrointestinal disturbances. Hence, there is a growing need for safer and effective complementary therapies. The present study aims to evaluate the add-on effect of the classical Kutajadi Tablet in the management of type 2 diabetes mellitus. This formulation is described in Prameha Chikitsa (Chikitsa Adhyaya 11, Shloka 8) of Sushruta Samhita and is believed to possess potential antihyperglycemic properties. The study intends to explore its therapeutic efficacy as a complementary approach in the management of diabetes mellitus type 2.
Study time - 90 days
Follow up - 0, 30, 60, 90
Total duration of study - 18 months
 
Close